First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Telix Pharmaceuticals has announced the dosing of the first patient in a Phase II study of TLX250-CDx, an imaging agent that targets carbonic anhydrase (CAIX) and is being investigated across a range of cancer indications. The STARBURST study will explore CAIX expression in patients with diverse solid tumours for potential diagnostic and therapeutic applications. Tumours expressing CAIX are typi..